The FDA’s ap­provalfor Cel­cu­ity’s can­cer drug Revtor­pyk on Tues­day was wide­ly an­tic­i­pat­ed. What Wall Street didn’t ex­pect was that the drug could take un­til...

A num­ber of mid­size biotech com­pa­nies have met with White House and HHS of­fi­cials in the last week, pre­sent­ing their case for why two pend­ing...

Last sum­mer, ze­ro biotechs made it on­to the pub­lic mar­kets as the in­dus­try weath­ered a sev­en-month dry spell for ini­tial share sales. This time around...

LON­DON— Over the past sev­er­al years, da­ta sci­en­tists search­ing through na­tion­al health records have no­ticed some­thing sur­pris­ing about peo­ple who had been vac­ci­nat­ed for...

In a ma­jor stum­ble for GSK’s $2 bil­lion ac­qui­si­tion of Bel­lus Health, the UK phar­ma saidFri­day it is end­ing de­vel­op­ment of cam­lip­ix­ant in re­frac­to­ry...

→ Sil­via Luque an­nounced on LinkedIn that she was named head of US mar­ket­ing at Zealand Phar­maaf­ter 13 years in var­i­ous roles at obe­si­ty...